Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The Acute Effect of Resistance Exercise in Individuals With Hypertrophic Cardiomyopathy: A Pilot Study.

The American journal of cardiology·2026
Same author

Prevalence and Predictors of Cardiac Troponin Elevations Following Exercise: a Systematic Review, Meta-analysis, and Meta-regression.

European journal of preventive cardiology·2026
Same author

Sudden Cardiac Arrest in Athletes.

The New England journal of medicine·2026
Same author

Masters athletes with abnormal cardiovascular findings: a clinical consensus statement of the European Association of Preventive Cardiology of the ESC and the American College of Cardiology.

European heart journal·2026
Same author

Masters Athletes With Abnormal Cardiovascular Findings: A Clinical Consensus Statement of the European Association of Preventive Cardiology of the ESC and the American College of Cardiology.

Journal of the American College of Cardiology·2026
Same author

Syncope During Cycling.

JACC. Case reports·2026

相关实验视频

Updated: Jul 6, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

达丁类药物相关的肌肉病变.

Paul D Thompson1, Priscilla Clarkson, Richard H Karas

  • 1Preventive Cardiology and Cardiovascular Research, Division of Cardiology, Hartford Hospital, Hartford, Conn 06102, USA. pthomps@harthosp.org

JAMA
|April 4, 2003
PubMed
概括
此摘要是机器生成的。

类药物可以引起肌肉问题,从轻微的疼痛到严重的狂肌痛. 风险因素和药物相互作用可能会增加这些不良影响,其机制仍在研究中.

相关实验视频

Last Updated: Jul 6, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

科学领域:

  • 药理学 药理学是指药理学的学科.
  • 毒理学 毒理学 毒理学
  • 临床医学 临床医学

背景情况:

  • 类他类药物,HMG-CoA减少酶抑制剂,广泛用于胆固醇管理.
  • 这些药物与一系列骨肌肉疾病有关,从肌痛到狂肌痛.
  • 了解这些不良影响对于患者的安全和有效的降脂疗法至关重要.

研究的目的:

  • 为提供关于他类药物相关肌肉病的临床总结.
  • 讨论潜在的机制,基础的他类药物诱导的肌肉损伤.
  • 更新使用FDA数据的关于他类药物相关性拉布地质溶解的报告.

主要方法:

  • 通过PubMed (截至2002年11月) 对他类肌肉病学文章的文献评论.
  • 关于他类药物的临床试验,病例系列和综述的综述 (PubMed至2003年1月).
  • 分析FDA MEDWATCH关于他类药物相关性狂犬病的不良事件报告 (1990年1月 - 2002年3月).

主要成果:

  • 在他类药物临床试验中,肌肉问题很少出现.
  • 美国食品和药物管理局 (FDA) 的MEDWATCH系统记录了3339例与他类药物相关的狂肌溶解病例,其中黄是最受影响的.
  • 关于较不严重的肌肉症状 (疼痛,软弱) 的数据表明患病率为1-5%;危险因素和药物相互作用 (例如,gemfibrozil) 可能会加剧不良反应.

结论:

  • 类他类药物相关肌肉病包括一系列肌肉问题,包括罕见但严重的狂肌病.
  • 器官功能障碍,并发症和药物相互作用等因素显著影响肌肉病的风险.
  • 虽然机制尚未完全阐明,但他类药物可能会通过减少调节性蛋白质生产来损害肌细胞维护.